Wenting Zhao

Postdoctoral Research Scientist at Columbia University

Research Expertise

Biotechnology

Synthetic Biology

Protein Engineering

Drug Screening

Cancer Research

Oncology

Molecular Medicine

Genetics

Genetics (clinical)

Molecular Biology

Biomedical Engineering

Neurology (clinical)

Cardiology and Cardiovascular Medicine

Advanced and Specialized Nursing

Immunology

Immunology and Allergy

Biochemistry

Bioengineering

About

Wenting Zhao is a highly educated and experienced individual in the field of Chemical and Biomolecular Engineering. She received her Bachelor of Science degree in Chemical and Bioengineering from Zhejiang University in 2010. She then went on to pursue her passion for research and obtained her PhD in Chemical and Biomolecular Engineering from Rice University in 2017. After completing her PhD, Wenting continued to expand her knowledge and skills as a Postdoctoral Research Scientist at Columbia University. She has been involved in numerous research projects and has published several papers in reputable scientific journals. Wenting's areas of expertise include biotechnology, drug discovery, synthetic biology, and next-generation sequencing. She is dedicated to finding innovative solutions to complex engineering problems and has a strong passion for making a positive impact through her research. In her free time, Wenting enjoys hiking, traveling, and trying new cuisines. She also enjoys mentoring and volunteering in STEM programs to inspire and empower young students to pursue careers in science and engineering.

Legacy Map

Full View

Publications

Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities

Nature Cancer

2021

Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker

Genome Medicine

2021

Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq

Genome Medicine

2021

ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

Nature Cancer

2021

Quantitatively Predictable Control of Cellular Protein Levels through Proteasomal Degradation

ACS Synthetic Biology

2017

Sensitive detection of proteasomal activation using the Deg-On mammalian synthetic gene circuit

Nature Communications

2014

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial

The Lancet Oncology

2022

Input-dependent post-translational control of the reporter output enhances dynamic resolution of mammalian signaling systems

Methods in Enzymology

2019

Single-cell based elucidation of molecularly-distinct glioblastoma states and drug sensitivity

Unknown Venue

2019

Hysteretic Genetic Circuit for Detection of Proteasomal Degradation in Mammalian Cells

ACS Synthetic Biology

2019

CTNI-25. PHASE IB CLINICAL TRIAL OF CHRONIC CONVECTION-ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT GLIOBLASTOMA

Neuro-Oncology

2020

TAMI-57. INDUCTION OF FERROPTOSIS PROMOTES IMMUNOGENIC CELL DEATH AND ACTIVATION OF THE IMMUNE MICROENVIRONMENT IN GLIOMA

Neuro-Oncology

2021

A cell state specific metabolic vulnerability to GPX4-dependent ferroptosis in glioblastoma

Unknown Venue

2023

Consensus scHPF Identifies Cell Type-Specific Drug Responses in Glioma by Integrating Large-Scale scRNA-seq

Unknown Venue

2023

Abstract 102: Microanatomy of Intracranial Human Thrombi by Single Nuclei Transcriptomics

Stroke

2024

TMIC-24. FERROPTOSIS INDUCES IMMUNOGENIC CELL DEATH AND SYNERGIZES WITH CD47 BLOCKADE TO REPROGRAM THE GLIOMA MICROENVIRONMENT

Neuro-Oncology

2023

Multiplexed single-cell lineage tracing of mitotic kinesin inhibitor resistance in glioblastoma

Unknown Venue

2023

A lymph node slice culture model to characterize T cell activation dynamics and anti-viral responses in human tissue

The Journal of Immunology

2023

ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

WFNOS 2022 Abstract Book

2022

Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

Nature Cancer

2022

TAMI-70. METABOLIC VULNERABILITY TO GPX4 INHIBITION AND FERROPTOSIS OF QUIESCENT ASTROCYTE-LIKE GLIOMA CELL POPULATIONS

Neuro-Oncology

2021

BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA

Neuro-Oncology

2021

MODL-09. FEASIBILITY OF ACUTE SLICE CULTURE-SINGLE CELL SEQUENCING DRUG SCREENING AS A TOOL TO SELECT THERAPY FOR CHILDREN WITH RELAPSED BRAIN TUMORS

Neuro-Oncology

2020

COMP-12. SINGLE-CELL TRANSCRIPTOME PROFILING OF GBM TISSUE ACUTE SLICE CULTURES FOR PERSONALIZED DRUG SCREENING

Neuro-Oncology

2019

A yeast selection system for the detection of proteasomal activation

Protein Engineering, Design and Selection

2018

Education

Rice University

PhD, Chemical and Biomolecular Engineering / August, 2017

Houston

Zhejiang Library

BS, Chemical and bioengineering / June, 2010

Zhejiang

Experience

Columbia University

Postdoctoral Research Scientist / September, 2017 — Present

Links & Social Media

My Bibliography

ORCID

Join Wenting on NotedSource!

Join Now

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.